A retrospective study of intravenous sodium stibogluconate alone and in combinations with allopurinol, rifampicin, and an immunomodulator in the treatment of Indian post-kala-azar dermal leishmaniasis

Indian Journal of Dermatology, Venereology and Leprology

Volumn 76, Issue 2, 2010, Pages 138-144

  Ramesh, V ^a   Kumar, Joginder ^a   Kumar, Dhiraj ^a   Salotra, Poonam ^a  

^a SAFDARJUNG HOSPITAL   (India)

Author keywords

Allopurinol; Kala azar; Leishmania donovani; Mw vaccine; Post kala azar dermal leishmaniasis; Rifampicin; Sodium stibogluconate; Visceral leishmaniasis

Indexed keywords

ALLOPURINOL; IMMUNOMODULATING AGENT; IMMUVAC; MW VACCINE; RIFAMPICIN; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG; VACCINE; ANTIMONY GLUCONATE; IMMUNOLOGIC FACTOR;

ADULT; ANOREXIA; ARTHRALGIA; ARTICLE; DIZZINESS; DRUG WITHDRAWAL; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INDIA; LEISHMANIASIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; RETROSPECTIVE STUDY; SKIN LEISHMANIASIS; TASTE DISORDER; THROMBOPHLEBITIS; TREATMENT OUTCOME; VACCINATION; VISCERAL LEISHMANIASIS; VOMITING; ADOLESCENT; AGED; COMPARATIVE STUDY; DRUG COMBINATION; FOLLOW UP; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALLOPURINOL; ANTIMONY SODIUM GLUCONATE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INDIA; INFUSIONS, INTRAVENOUS; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIFAMPIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77949835319     PISSN: 03786323     EISSN: 09733922     Source Type: Journal    
DOI: 10.4103/0378-6323.60553     Document Type: Article

References (31)

1. World Health Organization, 1990. Control of the Leishmaniases. Tech. Rep. Ser.No. 793. Geneva, Switzerland.
2. Mukherjee A, Ramesh V, Misra RS. Post-kala-azar dermal leishmaniasis. A light and electronmicroscopic study of 18 cases. J Cut Pathol 1993;20:320-325
3. Singh N, Ramesh V, Arora VK, Bhatia A, Kubba A, Ramam M. Nodular post-kala-azar dermal leishmaniasis: a distinct histopathologic entity. J Cut Pathol 1998;25:95-99
4. Ramesh V, Misra RS, Saxena U, Mukherjee A. Post-kala-azar dermal leishmaniasis: a clinical and therapeutic study. Int J Dermatol 1993;32:272-275
5. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992;46:296-306.
6. Thakur CP, Kumar K, Sinha PK, Mishra BN, Pandey AK. Treatment of post-kala-azar dermal leishmaniasis with sodium stibogluconate. Br Med J 1987;295:886-887
7. Thakur CP, Kumar K. Efficacy of prolonged therapy with stibogluconate in post-kala-azar dermal leishmaniasis. Indian J Med Res 1990;91:144-148
8. Ramesh V, Saxena U, Misra RS. Efficacy of ketoconazole in postkala- azar dermal leishmaniasis. Arch Dermatol 1992;128:411-412
9. Ramesh V. Allopurinol therapy in post-kala-azar dermal leishmaniasis. Acta Derm Venereol 1996;76:328-329
10. Muigai R, Gachihi GS, Oster CN, Were JB, Nyakundi PM, Chunge CN, et al. Post-kala-azar dermal leishmaniasis: the Kenyan experience. East Afr Med J 1991;68:801-806
11. Zijlstra EE, Musa AM, Khalil EAG, El Hassan IM, El-Hassan AM. Post-kala-azar dermal leishmaniasis. Lancet Inf Dis 2003;3:87-98.
12. Zijlstra EE, Khalil EA, Kager PA, El-Hassan AM. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis. Br J Dermatol 2000;143:136-143
13. Musa AM, Khalil EA, Mahgoub FA, Hamad S, Elkadaru AM, El Hassan AM. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL). Ann Trop Med Parasitol 2005;99:563-569
14. el Hassan AM, Ghalib HW, Zijlstra EE, Eltoum IA, Satti M, Ali MS, et al. Post-kala-azar dermal leishmaniasis in the Sudan: clinical features, pathology and treatment. Trans R Soc Trop Med Hyg 1992;86:245-248
15. Musa AM, Khalil EA, Mahgoub FA, Elgawi SH, Modabber F, Elkadaru AE, et al. Immunochemotherapy of persistent postkala- azar dermal leishmaniasis: a novel approach to treatment. Trans R Soc Trop Med Hyg 2008;102:58-63.
16. Reddi P, Amol A, Kandekar PS, Talwar GP. Molecular definition of unique species status of Mycobacterium w, a candidate antileprosy vaccine. Int J Lep Other Mycobact Dis 1994;62:229-236
17. Ramesh V, Singh R, Salotra P. Short communication: post-kalaazar dermal leishmaniasis--an appraisal. Trop Med Int Health 2007;12:848-851
18. Rathi SK, Pandhi RK, Khanna N, Chopra P. Therapeutic trial of sodium antimony gluconate alone and in combination with ketoconazole in post-kala-azar dermal leishmaniasis (PKDL). Indian J Dermatol Venereol Leprol 2003;69:692-693
19. Singh R, Kumar D, Ramesh V, Negi NS, Singh S, Salotra P. Visceral leishmaniasis or Kala-azar (KA): High incidence of refractoriness is contributed by anthroponotic transmission via post-KA dermal leishmaniasis. J Infect Dis 2006;194:302-306
20. Thakur CP, Narain S, Kumar N, Hassan SM, Jha DK, Kumar A. Amphotericin B is superior to sodium antimony gluconate in the treatment of post-kala-azar dermal leishmaniasis. Ann Trop Med Parasitol 1997;91:611-616
21. Sundar S, Chatterjee M. Visceral leishmaniasis - current therapeutic modalities. Indian J Med Res 2006;123:345-352
22. Napier LE. The Principles and Practice of Tropical Medicine: Kala-azar Macmillan, New York: 1946. p. 137-177
23. Garg VK, Agrawal S, Rani S, Joshi A, Agarwalla A, Das ML, et al. Post-kala-azar dermal leishmaniasis in Nepal. Int J Dermatol 2001;40:179-184
24. Wortmann G, Miller RS, Oster C, Jackson J, Aronson N. A randomized, doubleblind study of the efficacy of a 10- or 20- day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis 2002;35:261-267
25. Lawn SD, Armstrong M, Chilton D, Whitty CJ. Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaenous and mucosal leishmaniasis among returned travelers. Trans R Soc Trop Med Hyg 2006;100:264-269
26. Delgado J, Macías J, Pineda JA, Corzo JE, González-Moreno MP, de la Rosa R, et al. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1 infected patients. Am J Trop Med Hyg 1999;61766-61769
27. Sharma VK, Prasad HR, Sethuraman G, Khaitan BK. Combination of sodium stibogluconate and rifampicin in postkala- azar dermal leishmaniasis. Indian J Dermatol Venereol Leprol 2007;73:53-54
28. Black CD, Watson GJ, Ward RJ. The use of Pentostam liposomes in the chemotherapy of experimental leishmaniasis. Trans R Soc Trop Med Hyg 1977;71:550-552
29. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006;19:111-126
30. Ramesh V, Mukherjee A. Post-kala-azar dermal leishmaniasis. Int J Dermatol 1995;34: 85-91.
31. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol 2006;22:552-557